BiotechTube
Carbon Biosciences

Carbon Biosciences

Waltham, United States· Est.
carbonbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $76M

Overview

Carbon Biosciences is a private, preclinical-stage biotech leveraging its engineered parvovirus (parvovector) platform to create next-generation gene therapies. The company's initial focus is on cystic fibrosis, where its vector aims to deliver the full CFTR gene more effectively than current options. Founded in 2019 and backed by notable life science investors, Carbon is positioning its platform to address a range of genetic disorders with high unmet need. Its approach seeks to improve upon AAV vectors by allowing for larger transgenes and potentially redosable administration.

Cystic FibrosisGenetic Diseases

Technology Platform

Proprietary engineered parvovirus (parvovector) platform designed for larger genetic payload capacity (>5kb), targeted tissue tropism, and lower pre-existing immunity compared to AAV vectors.

Funding History

2
Total raised:$76M
Series A$38M
Seed$38M

Opportunities

The parvovector platform addresses key limitations of AAV, opening the large and growing gene therapy market for diseases requiring big genetic payloads, like cystic fibrosis.
Successful clinical validation could lead to high-value partnerships or acquisition by a large pharma company.
The potential for re-dosing could create a significant long-term competitive and commercial advantage.

Risk Factors

High preclinical/clinical development risk for an unproven viral vector platform.
Intense competition from other gene therapy modalities and improved AAV vectors.
Heavy reliance on venture funding in a volatile capital market, with value concentrated in a single lead program.

Competitive Landscape

Carbon competes in the gene therapy vector space, dominated by AAV platforms from companies like Spark Therapeutics (Roche) and REGENXBIO. For cystic fibrosis, it faces competition from other gene therapy approaches (e.g., 4D Molecular Therapeutics, ReCode Therapeutics) and highly effective small molecule CFTR modulators (Vertex Pharmaceuticals). Its differentiation lies in payload size and potential immune profile advantages.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →